Skip to content

Characterization of Endothelial Dysfunction as a Function of Hyperaemia of the Brachial Artery During Cardiac Surgery

Characterization of Endothelial Dysfunction as a Function of Hyperaemia of the Brachial Artery During Cardiac Surgery

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02853682
Acronym
GLYNO
Enrollment
28
Registered
2016-08-03
Start date
2016-01-20
Completion date
2021-01-30
Last updated
2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Capillary Leak Syndrome

Keywords

glycocalyx, capillary leak syndrome

Brief summary

The glycocalyx is a layer of proteins and complex sugars covering the endothelium of vessels. Its role as capillary filtration control is important. In case of alteration of the glycocalyx, experimental models and some clinical studies show an increased capillary leak responsible for interstitial edema. The analysis of glycocalyx in routine care is important to guide volume expansion. Indeed, the literature provides evidence about the poor prognosis of excess water and its impact on organ. This analysis challenge is to justify filling solution of choice according to the characteristic of this capillary leakage.

Detailed description

Extra corporeal circulation and aortic clamp induce ischemia-reperfusion damages. Vascular damages are represented by first glycocalyx, a layer of endovascular vessel proteoglycans, responsible for fluid permeability and secondly by nitro oxygen liberation responsible for vascular tonus. The investigators suppose that both functions are impaired after cardiac surgery.

Interventions

BIOLOGICALplasma

assesment of glycocalyx protein

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* cardiac surgery

Exclusion criteria

* auricular fibrillation * endocarditis * aortic dissection * end stage chronic renal disease

Design outcomes

Primary

MeasureTime frameDescription
glycocalyx proteins 148 hoursproteoglycan in patient plasma is assayed.

Countries

France

Contacts

PRINCIPAL_INVESTIGATOROsama ABOU ARAB, MD

CHU Amiens

STUDY_DIRECTOREmmanuel LORNE, MD-PhD

CHU Amiens

PRINCIPAL_INVESTIGATORPierre-Gregoire GUINOT, MD

CHU Amiens

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026